Indaptus Therapeutics | 8-K: Current report
Indaptus Therapeutics | 424B5: Prospectus
Indaptus Therapeutics | 10-K: Annual report
Indaptus Therapeutics | 8-K: Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Indaptus Therapeutics | 8-K: Current report
Indaptus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Newman Michael James
Indaptus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Meckler Jeffrey A
Indaptus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Sassi Nir
Indaptus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Waltzman Roger J.
Indaptus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Linscott Walt Addison
Indaptus Therapeutics | 8-K: Current report
Indaptus Therapeutics: Q3 2023 Earnings Report
Indaptus Therapeutics | 8-K: Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Indaptus Therapeutics | 8-K: Current report
Indaptus Therapeutics | 8-K: Current report
Indaptus Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Anderson Glen R.
Indaptus Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Glen R. Anderson(14.17%)
Indaptus Therapeutics | 10-Q: Q2 2023 Earnings Report
Indaptus Therapeutics | 8-K: Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Indaptus Therapeutics | 8-K: Current report
No Data